Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer

Bushra Haq, Charles E. Geyer

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Amplification of the human epidermal growth factor receptor 2 (HER2) gene occurs in 18-23% of invasive breast carcinomas and is associated with a worse prognosis. This novel transforming gene was identified in 1985, and in 1987 HER2 amplification was demonstrated to be central to the aggressive, malignant phenotype of these cancers and a significant predictor of both time to relapse and overall survival. These observations led to the development of the first monoclonal antibody targeting the extracellular domain of HER2, trastuzumab (Herceptin®, Genentech and Hoffman LaRoche, Switzerland), which was approved by the US FDA for metastatic breast cancer in 1998. In 2005, results from four major trastuzumab adjuvant trials demonstrated a marked reduction in risk of recurrence, and trastuzumab is now an essential component of the adjuvant treatment of HER2-positive early breast cancer. Concerns regarding cardiac safety and mechanisms of resistance to trastuzumab remain important issues and are being addressed in ongoing research efforts.

Original languageEnglish (US)
Pages (from-to)135-147
Number of pages13
JournalWomen's Health
Volume5
Issue number2
DOIs
StatePublished - 2009

Fingerprint

Breast Neoplasms
erbB-1 Genes
Recurrence
Risk Reduction Behavior
Switzerland
Oncogenes
Monoclonal Antibodies
human ERBB2 protein
Trastuzumab
Phenotype
Safety
Research
Neoplasms

Keywords

  • Adjuvant therapy
  • Anthracyclines
  • Breast cancer
  • Cardiotoxicity
  • HER2 positive
  • Trastuzumab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer. / Haq, Bushra; Geyer, Charles E.

In: Women's Health, Vol. 5, No. 2, 2009, p. 135-147.

Research output: Contribution to journalArticle

Haq, Bushra ; Geyer, Charles E. / Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer. In: Women's Health. 2009 ; Vol. 5, No. 2. pp. 135-147.
@article{e19401ff1f674641b506052f01086fdb,
title = "Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer",
abstract = "Amplification of the human epidermal growth factor receptor 2 (HER2) gene occurs in 18-23{\%} of invasive breast carcinomas and is associated with a worse prognosis. This novel transforming gene was identified in 1985, and in 1987 HER2 amplification was demonstrated to be central to the aggressive, malignant phenotype of these cancers and a significant predictor of both time to relapse and overall survival. These observations led to the development of the first monoclonal antibody targeting the extracellular domain of HER2, trastuzumab (Herceptin{\circledR}, Genentech and Hoffman LaRoche, Switzerland), which was approved by the US FDA for metastatic breast cancer in 1998. In 2005, results from four major trastuzumab adjuvant trials demonstrated a marked reduction in risk of recurrence, and trastuzumab is now an essential component of the adjuvant treatment of HER2-positive early breast cancer. Concerns regarding cardiac safety and mechanisms of resistance to trastuzumab remain important issues and are being addressed in ongoing research efforts.",
keywords = "Adjuvant therapy, Anthracyclines, Breast cancer, Cardiotoxicity, HER2 positive, Trastuzumab",
author = "Bushra Haq and Geyer, {Charles E.}",
year = "2009",
doi = "10.2217/17455057.5.2.135",
language = "English (US)",
volume = "5",
pages = "135--147",
journal = "Women's health (London, England)",
issn = "1745-5065",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer

AU - Haq, Bushra

AU - Geyer, Charles E.

PY - 2009

Y1 - 2009

N2 - Amplification of the human epidermal growth factor receptor 2 (HER2) gene occurs in 18-23% of invasive breast carcinomas and is associated with a worse prognosis. This novel transforming gene was identified in 1985, and in 1987 HER2 amplification was demonstrated to be central to the aggressive, malignant phenotype of these cancers and a significant predictor of both time to relapse and overall survival. These observations led to the development of the first monoclonal antibody targeting the extracellular domain of HER2, trastuzumab (Herceptin®, Genentech and Hoffman LaRoche, Switzerland), which was approved by the US FDA for metastatic breast cancer in 1998. In 2005, results from four major trastuzumab adjuvant trials demonstrated a marked reduction in risk of recurrence, and trastuzumab is now an essential component of the adjuvant treatment of HER2-positive early breast cancer. Concerns regarding cardiac safety and mechanisms of resistance to trastuzumab remain important issues and are being addressed in ongoing research efforts.

AB - Amplification of the human epidermal growth factor receptor 2 (HER2) gene occurs in 18-23% of invasive breast carcinomas and is associated with a worse prognosis. This novel transforming gene was identified in 1985, and in 1987 HER2 amplification was demonstrated to be central to the aggressive, malignant phenotype of these cancers and a significant predictor of both time to relapse and overall survival. These observations led to the development of the first monoclonal antibody targeting the extracellular domain of HER2, trastuzumab (Herceptin®, Genentech and Hoffman LaRoche, Switzerland), which was approved by the US FDA for metastatic breast cancer in 1998. In 2005, results from four major trastuzumab adjuvant trials demonstrated a marked reduction in risk of recurrence, and trastuzumab is now an essential component of the adjuvant treatment of HER2-positive early breast cancer. Concerns regarding cardiac safety and mechanisms of resistance to trastuzumab remain important issues and are being addressed in ongoing research efforts.

KW - Adjuvant therapy

KW - Anthracyclines

KW - Breast cancer

KW - Cardiotoxicity

KW - HER2 positive

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=67650157414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650157414&partnerID=8YFLogxK

U2 - 10.2217/17455057.5.2.135

DO - 10.2217/17455057.5.2.135

M3 - Article

C2 - 19245352

AN - SCOPUS:67650157414

VL - 5

SP - 135

EP - 147

JO - Women's health (London, England)

JF - Women's health (London, England)

SN - 1745-5065

IS - 2

ER -